Related Experiment Video
Updated: Aug 15, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Rituximab treatment of refractory rheumatoid arthritis
Kelly M Summers1, Denise R Kockler
1Adult Internal Medicine Pharmacy Resident, Virginia Commonwealth University Medical Center/Medical College of Virginia Hospitals, Richmond, 23298, USA.
Objective:
To review published literature using rituximab for treatment of refractory rheumatoid arthritis (RA).
Data Sources:
An English-language literature search was conducted using MEDLINE (1966-May 2005) and EMBASE (1980-May 2005). References of identified articles were subsequently reviewed for additional data.
Data Synthesis:
Evidence suggests that B lymphocyte depletion in patients suffering from refractory RA may be a key component in the interruption of the disease pathogenesis. Successful depletion of B lymphocytes with rituximab in patients with RA has been reported in case reports, open-label pilot studies, and a randomized, double-blind, placebo-controlled trial.
Conclusions:
Based on the limited published data, rituximab, when used in combination with other agents (ie, cyclophosphamide or methotrexate), appears to be a reasonable treatment option for refractory RA. However, additional controlled trials need to be conducted to further define optimal dosing, response rates, comparative long-term efficacy, and RA treatment algorithm placement of rituximab in this patient population.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Cardiomyopathy IV: Restrictive Cardiomyopathy
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Rheumatic Heart Disease I: Introduction